Clinical trials: RNA Viruses
Covid19
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress
This is a Phase 2 study to assess COVI-MSC in the setting of current standard of care in hospitalized subjects with RT-PCR confirmed SARS-CoV-2 (COVID-19) infection and acute respiratory distress / acute respiratory distress…
- Trial name
- NCT04905836
- Testing
- COVI-MSC
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sorrento Therapeutics, Inc.
HIV Infections
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens.
- Trial name
- PEARLS (NCT00084136)
- Testing
- Atazanavir, Didanosine (enteric-coated), Efavirenz
- Where
- 42 sites in United States, Brazil and 7 more
- Volunteers
- 1,571 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Chronic Hepatitis C
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
The purpose of the study is to determine whether therapy with the combination of PSI-7977 and daclatasvir (BMS-790052) with or without ribavirin is effective in treating hepatitis C virus (HCV) infection when given for 12 or 24…
- Trial name
- NCT01359644
- Testing
- PSI-7977, Daclatasvir, Ribavirin
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Covid19
Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19)
The purpose of this study is to describe balance deficits in patients post COVID-19. The information the investigators learn may help influence balance training exercises for patients post-COVID-19.
- Trial name
- NCT04914364
- Testing
- Balance assessments
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Duke University
Influenza, H7N9 Influenza
Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil
The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen formulated with 2 different adjuvants .
- Trial name
- NCT03330899
- Testing
- H7N9 antigen + adjuvant IB160, H7N9 antigen + adjuvant SE, H7N9 antigen without adjuvant
- Where
- 3 sites in Brazil
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Hepatitis C
Study of the Immune Response to Hepatitis C Virus
The purpose of this study is to investigate the mechanism of a successful immune response to hepatitis C virus (HCV) infection. Currently, it is believed that the immune system is involved in responding to HCV infection, but how…
- Trial name
- NCT00237432
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Rockefeller University
HIV Infections
Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children
Cohort I: The purpose of this study is to see how safe it is to combine 2 anti-HIV medications, efavirenz (EFZ) and nelfinavir (NFV) to treat HIV-positive children and to find an appropriate dose of EFZ to use in combination with…
- Trial name
- NCT00000893
- Testing
- Nelfinavir mesylate, Efavirenz
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 103 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, Trauma
Trauma Informed Intervention to Support Engagement in HIV Care Among MSM (THRIVE+)
This purpose of this project is to specify and provide an initial test of a 10 session, individual-based cognitive therapy intervention to address symptoms of PTSD and poor engagement in HIV care among men who have sex with men…
- Trial name
- THRIVE+ (NCT05822206)
- Testing
- CBT-TSC, Life Steps and Sexual Decision-Making
- Where
- 2 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Acute Respiratory Distress Syndrome
Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU
Renal damage in patients hospitalized for ARDS in the ICU can also be related to multiple causes including, but not limited to, the consequences of hemodynamic fluctuations in these patients or the use of nephrotoxic drugs…
- Trial name
- PR-Covid-19 (NCT04385004)
- Where
- France
- Volunteers
- 320 people
- Sponsor
- University Hospital, Strasbourg, France
HIV/AIDS, Clinical Depression
Zaleplon in HIV Patients With Depression
In HIV positive patients with sleep onset insomnia and receiving pharmacologic treatment for comorbid depression, the proposed study aims to evaluate the impact of zaleplon on sleep measures determined by insomnia severity index…
- Trial name
- NCT03489304
- Testing
- Zaleplon
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
HIV Infections
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
To extend the evaluation of safety and immunogenicity of MN recombinant soluble gp120/HIV-1 (MN rsgp120/HIV-1) in combination with QS21 with or without alum and on two different vaccination schedules.
- Trial name
- NCT00001052
- Testing
- Aluminum hydroxide, QS-21, rgp120/HIV-1MN
- Where
- 5 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Endothelial Dysfunction
The Glycocalyx in COVID-19 Patients. A Pilot Study
The damage of the endothelial glycocalyx is based on microvascular endothelial dysfunction and typical for critical clinical conditions like sepsis, trauma, bleeding, shock, as well as ARDS.
- Conditions
- COVID-19, Endothelial Dysfunction, Coagulation Disorder
- Trial name
- Glycovid-19 (NCT05137249)
- Where
- Austria
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
COVID-19
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a…
- Trial name
- VAT00008 (NCT04904549)
- Testing
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
- Where
- 86 sites in United States, Colombia and 9 more
- Volunteers
- 23,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Chikungunya Fever
Resistance Exercise Program on the Functionality of Individuals With Chikungunya Fever
Common symptoms of chikungunya fever are persistent arthritis and arthralgia, such symptoms can lead to impairment in functionality.
- Trial name
- NCT03702348
- Testing
- Resistance exercise
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Universidade Federal de Pernambuco
Dengue Hemorrhagic Fever, Awareness
Evaluating Public Awareness and Preventive Actions for Dengue Fever in Sudan Amidst Ongoing Crises
This study evaluates the awareness of dengue fever and preventive measures among Sudanese people during the war. It assesses knowledge, awareness, implementation of prevention, access to healthcare, community involvement, and the…
- Trial name
- NCT07205848
- Testing
- No intervention
- Where
- Sudan
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Research and Publication office
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
COVID-19
Impact of Long COVID-19 on the Health and Quality of Life of Military Personnel (Active or Retired) and Their Families
Severe and sometimes irreversible sequelae are observed in people who have developed a severe form of COVID-19 (pulmonary, cardiovascular, renal, neurological sequelae among others).
- Trial name
- IMP@LA (NCT05200832)
- Testing
- Online questionnaire, Semi-structured interview
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of
HCV Reinfection in HD Patients Achieving SVR
Among the hemodialysis units, the global incidence of HCV infection ranges from 1.2% to 2.9%. Data regarding the long-term risk of reinfection among hemodialysis patients achieving SVR are limited.
- Conditions
- Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Hemodialysis Complication
- Trial name
- NCT04732832
- Where
- 7 sites in Taiwan
- Volunteers
- 350 people
- Sponsor
- National Taiwan University Hospital
Pulmonary Disease, Influenza
An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study.
The proposed pilot study will provide needed data to establish the feasibility of a conducting a large randomized controlled trial as to the effectiveness of the use of oseltamivir early in the course of influenza in outpatients…
- Trial name
- AVT (NCT02282384)
- Testing
- oseltamivir
- Sponsor
- McMaster University
Chronic Illness
Intradermal Trivalent Influenza Vaccine With Imiquimod
Despite the WHO International Health Regulations Emergency Committee declared an end to the 2009 H1N1 pandemic globally, the emergence of the novel 2009 H1N1 virus in March 2009 has affected more than 214 countries with at least…
- Trial name
- NCT01508884
- Testing
- influenza vaccine, Imiquimod, Aqueous cream
- Where
- Hong Kong
- Volunteers
- 93 people
- Sponsor
- The University of Hong Kong